Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 578-582, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1014642
ABSTRACT
Hepatitis B virus (HBV) infection is a global public health problem, and the prevention of mother-to-child transmission (MTCT) is an important intervention method. As a new nucleoside reverse transcriptase inhibitor, tenofovir alafenamide (TAF) has the characteristics of strong liver targeting and low peripheral blood exposure. Although it has been used in the treatment of chronic hepatitis B widely, its application in blocking mother-to-child transmission of HBV is still limited. This paper reviews the characteristics of TAF, the effects of TAF on infants and pregnant women, in order to provide new ideas for the prevention of mother-to-child transmission of HBV.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS